A drug given to organ donors may help kidneys work faster after transplant

NCT ID NCT02907554

Completed Disease control Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This trial tests whether giving a single dose of cyclosporine A to deceased organ donors before their kidneys are removed can reduce the chance of delayed graft function in recipients. Delayed graft function means the kidney does not start working right away, often requiring dialysis. The study compares kidneys from donors who received cyclosporine A against those who received a placebo, tracking how well the kidneys function during the first year after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cyclosporine A given to the deceased organ donor before kidney removal
What this could lead to: If it works, this simple pretreatment could reduce the need for dialysis after kidney transplant and improve early graft function.
What could go wrong: This is a single-drug approach in a complex transplant setting; benefits may be modest or not outweigh risks like infection or kidney toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN DEATH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Brain Death chronic kidney disease Delayed Graft Function

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN DEATH KIDNEY TRANSPLANTATION

Contacts and locations

Locations

CHU Clermont-Ferrand

Clermont-Ferrand, 63003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.